Tags : Co-develop

Gilead Signs a Ten Years Agreement with Arcus to Co-Develop

Shots: Arcus to receive $375M including $175M up front & $200M as equity investment at a price of $33.54/ share with a premium of 35% and is eligible to receive $1.225B as in opt-in and milestones concerning its current clinical product candidates.  Gilead will support the ongoing research and development by paying $400M during the […]Read More

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the

Shots: Lilly will get an exclusive license to perform clinical development, manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of […]Read More

Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19

Shots: The companies collaborate to accelerate the development of BioNTech’s BNT162, which is anticipated to enter clinical studies by the end of Apr’2020. The alliance will leverage the expertise and resources of both companies to co-develop mRNA-based vaccine candidate globally (Ex- China) The collaboration follows 2018 agreement signed b/w the companies to develop mRNA-based vaccines […]Read More

AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting

Shots: The alliance will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA P3 program with Eli Lilly’s development & manufacturing capabilities. The companies will equally share the initial development cost while Lilly will be solely responsible for further development, manufacturing & distribution activities The companies have identified ~500+ unique Ab isolated from one […]Read More

Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for

Shots: The alliance will validate multiple biomarkers to be used in Thermo Fisher’s Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical studies focusing NSCLC and may follow other cancer indications The ability of the Oncomine Dx Target test to rapidly detect variants from small quantities of DNA/ […]Read More

BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat

Shots: The collaboration will deploy Voluntis’ Theraxium Oncology, a platform for digital therapies in oncology and will evaluate potential solutions to support the management of patients symptoms & remote monitoring by HCPs The focus of the collaboration is to develop digital therapies, providing patients access to a mobile app to support the treatment and track […]Read More

Codagenix Collaborates with Serum Institute of India to Co-Develop a

Shots: Codagenix will utilize its deoptimization technology for viral deoptimization, designed several nCoV vaccine candidate genomes, will grow and conduct in-vivo tests of vaccine viruses prior to testing in clinical studies The Serum Institute of India will scale up the manufacturing of vaccines to ensure its availability to meet the public needs. The companies are […]Read More

Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell

Shots: Adaptimmune to receive $50M up front, ~73.75M development milestones/ target (if product co-developed & co-commercialized by both companies) and $147.5M as milestones/product & $110M as commercial milestone if products developed by Astellas. Additionally, Adaptimmune to receive up to $7.5M/ yr. as research funding and royalties on net sales of the products Astellas to receive […]Read More

Gene Techno Science Signs an Agreement with Kishi Kasei to

Shots: GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines, which were jointly developed by GTS and Fuso Pharmaceutical The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share […]Read More